Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients

被引:12
作者
Almirall, J
Lopez, TS
Vallve, M
Ruiz, A
Llibre, J
Betriu, A
机构
[1] UAB, Nephrol Unit, Corp Sanitaria Parc Tauli, Inst Univ Parc Tauli, ES-08208 Sabadell, Spain
[2] CETIRSA, Terrassa, Spain
[3] Sistemes Renals, Lleida, Spain
来源
NEPHRON CLINICAL PRACTICE | 2004年 / 97卷 / 01期
关键词
hyperphosphataemia; dialysis; phosphate binders; cholesterol; sevelamer;
D O I
10.1159/000077591
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: The treatment of hyperphosphataemia is of major importance in the management of patients on dialysis. Traditional phosphate binders can be associated with undesirable effects. Recently, a new non-absorbable phosphate-binding polymer, sevelamer hydrochloride, has been available. Clinical information is scarce, and its cost could be a limiting factor for its wider use. No studies have evaluated its usefulness in uncontrolled hyperphosphataemic patients. Methods: We identified 34 patients with a maintained serum phosphorus concentration 16.5 mg/dl and/or toxicity related to standard phosphorus-binding treatment (aluminium or calcium based). Sevelamer was added and titrated up fortnightly to achieve phosphorus control. Previous phosphate binders were decreased, whenever possible. The period of the study was 6 months. Results: Thirteen patients (38%) dropped out because of side effects, mainly related to the gastro-intestinal tract. The efficacy analysis disclosed that the phosphorus concentration decreased from 2.39+/-0.48 to 1.84+/-0.48 mmol/l (p<0.001). The mean dose of sevelamer was stabilised at 3.4 +/- 1.8 g/day. The amount of calcium- and aluminium-based phosphate binders could be decreased from 5.1 +/- 3.5 to 3.1 +/- 2.7 g/day (38% decrease) and from 2.4 +/- 1.5 to 1.5 +/- 1.7 g/day (36% decrease), respectively. The Ca x P product was significantly decreased from 5.83 +/- 1.19 to 4.36 +/- 1.12 mmol/l(2) (p<0.001). The total cholesterol concentration decreased from 4.34+/-0.9 to 3.98+/-0.9 mmol/l (p<0.01) and the low-density lipoprotein cholesterol level from 2.61 +/- 0.98 to 2.20 +/- 0.77 mmol/l (p<0.03). Conclusions: Sevelamer is an effective phosphate binder that allows a better serum phosphorus control, while allowing a decrease in the dose of calcium- and aluminium-based phosphate binders in these difficult patients. The drawbacks are the high intolerance rate and the price of the product. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:C17 / C22
页数:6
相关论文
共 33 条
[1]   CALCIUM ACETATE VERSUS CALCIUM-CARBONATE FOR THE CONTROL OF SERUM PHOSPHORUS IN HEMODIALYSIS-PATIENTS [J].
ALMIRALL, J ;
VECIANA, L ;
LLIBRE, J .
AMERICAN JOURNAL OF NEPHROLOGY, 1994, 14 (03) :192-196
[2]   CALCIUM-CARBONATE IS AN EFFECTIVE PHOSPHORUS BINDER IN CHILDREN WITH CHRONIC-RENAL-FAILURE [J].
ANDREOLI, SP ;
DUNSON, JW ;
BERGSTEIN, JM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1987, 9 (03) :206-210
[3]   INTRAVENOUS CALCITRIOL IN THE TREATMENT OF REFRACTORY OSTEITIS FIBROSA OF CHRONIC RENAL-FAILURE [J].
ANDRESS, DL ;
NORRIS, KC ;
COBURN, JW ;
SLATOPOLSKY, EA ;
SHERRARD, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (05) :274-279
[4]   Prediction of coronary events with electron beam computed tomography [J].
Arad, Y ;
Spadaro, LA ;
Goodman, K ;
Newstein, D ;
Guerci, AD .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (04) :1253-1260
[5]   A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients [J].
Bleyer, AJ ;
Burke, SK ;
Dillon, M ;
Garrett, B ;
Kant, KS ;
Lynch, D ;
Rahman, SN ;
Schoenfeld, P ;
Teitelbaum, I ;
Zeig, S ;
Slatopolsky, E .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) :694-701
[6]   Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[7]   Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401
[8]   RenaGel(R), a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers [J].
Burke, SK ;
Slatopolsky, EA ;
Goldberg, DI .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (08) :1640-1644
[9]   CALCIUM ACETATE VERSUS CALCIUM-CARBONATE AS PHOSPHATE BINDERS IN HEMODIALYSIS-PATIENTS [J].
CARAVACA, F ;
SANTOS, I ;
CUBERO, JJ ;
ESPARRAGO, JF ;
ARROBAS, M ;
PIZARRO, JL ;
ROBLES, R ;
SANCHEZCASADO, E .
NEPHRON, 1992, 60 (04) :423-427
[10]  
Chertow GM, 1999, CLIN NEPHROL, V51, P18